IGF-I Bioactivity Better Reflects Growth Hormone Deficiency than Total IGF-I

Context: GH is considered the main regulator of circulating IGF-I. Total (extractable) IGF-I is therefore routinely used for diagnosis of GH deficiency (GHD) and for monitoring treatment. Methods currently used for measurement of circulating total IGF-I may be hampered by interferences of IGF-bindin...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical endocrinology and metabolism 2011-07, Vol.96 (7), p.2248-2254
Main Authors: Varewijck, A. J, Lamberts, S. W. J, Uitterlinden, P, Hofland, L. J, Janssen, J. A. M. J. L
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Dwarfism, Pituitary - metabolism
Endocrinopathies
Feeding. Feeding behavior
Female
Fundamental and applied biological sciences. Psychology
Human Growth Hormone - deficiency
Human Growth Hormone - metabolism
Humans
Insulin-Like Growth Factor I - metabolism
Male
Medical sciences
Middle Aged
Vertebrates: anatomy and physiology, studies on body, several organs or systems
Vertebrates: endocrinology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Context: GH is considered the main regulator of circulating IGF-I. Total (extractable) IGF-I is therefore routinely used for diagnosis of GH deficiency (GHD) and for monitoring treatment. Methods currently used for measurement of circulating total IGF-I may be hampered by interferences of IGF-binding proteins. Recently a kinase receptor activation assay was developed to determine IGF-I bioactivity in human serum. The principle of this assay is based on quantification of IGF-I receptor activation after stimulation with serum in vitro. Objective: The objective of the study was to investigate the diagnostic potential of IGF-I bioactivity in adults with GHD. Design: This was a single-center observational study. Study Participants: Ninety-four GH-untreated patients diagnosed with GHD by GH-provocative tests were included. Main Outcome Measures: IGF-I bioactivity (determined by the IGF-I kinase receptor activation assay) and total IGF-I (determined by immunoassay) were measured in fasting blood samples. Results: IGF-I bioactivity was more frequently below the normal range (
ISSN:0021-972X
1945-7197
DOI:10.1210/jc.2011-0051